Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

49.37 -0.63 (-1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,657,636
Open 50.01
Bid (Size) 48.50 (300)
Ask (Size) 50.01 (300)
Prev. Close 50.00
Today's Range 48.59 - 50.65
52wk Range 27.07 - 61.76
Shares Outstanding 94,873,407
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
From Scholar Rock
Via Business Wire

Performance

YTD
+15.4%
+15.4%
1 Month
-5.1%
-5.1%
3 Month
+8.4%
+8.4%
6 Month
+21.3%
+21.3%
1 Year
+46.6%
+46.6%

More News

Read More
News headline image
Scholar Rock to Present at Upcoming Investor Conferences
From Scholar Rock
Via Business Wire
Scholar Rock (NASDAQ:SRRK) Rallies 17% as Regulatory Catalysts Outweigh In-Line Q2 Results ↗
Via Chartmill
News headline image
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab ↗
Via MarketBeat
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
News headline image
Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Economy
News headline image
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
From Scholar Rock, Inc.
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock, Inc.
Via Business Wire
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Scholar Rock (SRRK) Q1 2026 Earnings Transcript ↗
Via The Motley Fool

Frequently Asked Questions

Is Scholar Rock Holding Corporation - Common Stock publicly traded?
Yes, Scholar Rock Holding Corporation - Common Stock is publicly traded.
What exchange does Scholar Rock Holding Corporation - Common Stock trade on?
Scholar Rock Holding Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Scholar Rock Holding Corporation - Common Stock?
The ticker symbol for Scholar Rock Holding Corporation - Common Stock is SRRK on the Nasdaq Stock Market
What is the current price of Scholar Rock Holding Corporation - Common Stock?
The current price of Scholar Rock Holding Corporation - Common Stock is 49.37
When was Scholar Rock Holding Corporation - Common Stock last traded?
The last trade of Scholar Rock Holding Corporation - Common Stock was at 09/16/26 04:00 PM ET
What is the market capitalization of Scholar Rock Holding Corporation - Common Stock?
The market capitalization of Scholar Rock Holding Corporation - Common Stock is 4.68B
How many shares of Scholar Rock Holding Corporation - Common Stock are outstanding?
Scholar Rock Holding Corporation - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.